PCI 45227 is an active metabolite of the Bruton's tyrosine kinase inhibitor ibrutinib .1PCI 45227 is formed from ibrutinib by the cytochrome P450 (CYP) isoform CYP3A.
1.Veeraraghavan, S., Viswanadha, S., Thappali, S., et al.Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic studyJ. Pharm. Biomed. Anal.107151-158(2015)
(Rac)-IBT6A hydrochloride is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).
IBT6A hydrochloride, an impurity of Ibrutinib, is relevant for synthesizing IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM).